Department of Respiratory and Critical Care Medicine, West China Hospital, West China School of Medicine, Sichuan University, Chengdu, People's Republic of China.
Int J Chron Obstruct Pulmon Dis. 2022 Oct 12;17:2567-2575. doi: 10.2147/COPD.S374079. eCollection 2022.
Some clinical indicators have been reported to be useful in differentiating asthma-chronic obstructive pulmonary disease (COPD) overlap (ACO) from pure asthma/COPD, but the results were inconsistent. This study aims to evaluate the diagnostic value of these indicators for ACO.
Databases of PubMed, EMBASE, Ovid and Web of Science were retrieved. Pooled standardized mean differences (SMDs) with 95% confidence intervals (CIs) were calculated in random-effects models.
48 eligible studies were included. The pooled results indicated, compared with pure asthma, ACO patients had lower levels of forced expiratory volume in the first second (FEV)% predicted (pred) (SMD=-1.09, 95% CI -1.3 to -0.87), diffusion lung capacity for carbon monoxide (DLCO)% pred (SMD=-0.83, 95% CI -1.24 to -0.42), fractional exhaled nitric oxide (FeNO) (SMD=-0.23, 95% CI -0.36 to -0.11), and higher levels of induced sputum neutrophil (SMD = 0.51, 95% CI 0.21 to 0.81), circulating YKL-40 (SMD = 0.96, 95% CI 0.27 to 1.64). However, relative to COPD alone, ACO patients had higher levels of FEV% pred (SMD = 0.15, 95% CI 0.05 to 0.26), DLCO% pred (SMD = 0.38, 95% CI 0.16 to 0.6), FeNO (SMD = 0.59, 95% CI 0.40 to 0.78), serum total immunoglobulin (Ig)E (SMD = 0.42, 95% CI 0.1 to 0.75), blood eosinophil (SMD = 0.44, 95% CI 0.29 to 0.59), induced sputum eosinophil (SMD = 0.62, 95% CI 0.42 to 0.83), and lower levels of induced sputum neutrophil (SMD=-0.48, 95% CI -0.7 to -0.27), circulating YKL-40 (SMD=-1.09, 95% CI -1.92 to -0.26).
Compared with pure asthma/COPD, ACO patients have different levels of FEV% pred, DLCO% pred, FeNO, serum total IgE, blood eosinophil, induced sputum eosinophil/neutrophil, and circulating YKL-40, which could be helpful to establish a clinical diagnosis of ACO.
一些临床指标已被报道可用于区分哮喘-慢性阻塞性肺疾病(COPD)重叠(ACO)与单纯哮喘/COPD,但结果不一致。本研究旨在评估这些指标对 ACO 的诊断价值。
检索 PubMed、EMBASE、Ovid 和 Web of Science 数据库。采用随机效应模型计算标准化均数差值(SMD)及其 95%置信区间(CI)。
纳入 48 项符合条件的研究。汇总结果表明,与单纯哮喘相比,ACO 患者的一秒率(FEV)%预计值(SMD=-1.09,95%CI-1.3 至-0.87)、一氧化碳弥散量(DLCO)%预计值(SMD=-0.83,95%CI-1.24 至-0.42)、呼出气一氧化氮(FeNO)(SMD=-0.23,95%CI-0.36 至-0.11)较低,诱导痰中性粒细胞(SMD=0.51,95%CI 0.21 至 0.81)和血清 YKL-40(SMD=0.96,95%CI 0.27 至 1.64)水平较高。然而,与 COPD 相比,ACO 患者的 FEV%预计值(SMD=0.15,95%CI 0.05 至 0.26)、DLCO%预计值(SMD=0.38,95%CI 0.16 至 0.6)、FeNO(SMD=0.59,95%CI 0.40 至 0.78)、血清总免疫球蛋白(IgE)(SMD=0.42,95%CI 0.1 至 0.75)、血嗜酸性粒细胞(SMD=0.44,95%CI 0.29 至 0.59)、诱导痰嗜酸性粒细胞(SMD=0.62,95%CI 0.42 至 0.83)水平较高,而诱导痰中性粒细胞(SMD=-0.48,95%CI-0.7 至-0.27)、血清 YKL-40(SMD=-1.09,95%CI-1.92 至-0.26)水平较低。
与单纯哮喘/COPD 相比,ACO 患者的 FEV%预计值、DLCO%预计值、FeNO、血清总 IgE、血嗜酸性粒细胞、诱导痰嗜酸性粒细胞/中性粒细胞和血清 YKL-40 水平不同,这可能有助于建立 ACO 的临床诊断。